29/05/2015 11:05:29 Cookie Policy Free Membership Login

Astrazeneca Share Chat - AZN

Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change Price Change % Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -53.00 -1.18% 4,439.00 4,439.00 4,440.00 4,512.50 4,434.00 4,490.00 370,074 10:50:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 16,751.4 799.9 62.9 69.4 56,074.27

Astrazeneca Bulletin Board

DateSubjectDiscuss
26/5/2015
22:51
Hi Everyone, I already hold AZN in my Income Portfolio and decided to Topup with a Long Spreadbet on them as well. Here is my Buy Rationale with Bull and Bear points, Valuation, Target and lots of simple Technical Analysis stuff. Hope you like it. cheers, WheelieD hTTp://www.wheeliedealer.weebly.com/blog
by thewheeliedealer on AstraZeneca
22/5/2015
12:06
what did they offer last time around ?
by chutes01 on AstraZeneca
21/5/2015
13:52
Pzier 58 bid city hot rumour.
by topcar on AstraZeneca
21/5/2015
07:44
Pzier are coming back here, allmost certain, smoke screen GSK they cannot afford GSK, AZN could be bought for GSK mkt Cap now !!Fact..pipeline AZN very strong.
by topcar on AstraZeneca
18/5/2015
19:25
446k, not a small investment
by mellowman62 on AstraZeneca
06/5/2015
15:16
Whats just happened here ? Bang on US opening, Pizer my bet, new goverment UK
by topcar on AstraZeneca
03/5/2015
07:03
That's the point. They bought them in the market at those prices. Shares awarded as part of an incentive/bonus scheme would be described as such and it would be stated that the shares would have to be held for a minimum period. Also, the transferees are non-execs. An example of bonus/incentive shares can be seen in the RNS dated 30th March 2015. Time horizons and criteria of awards are clearly stated.
by nisbet on AstraZeneca
02/5/2015
23:20
When I was getting them they were bought on the open market at the prevailing price
by gbb483 on AstraZeneca
02/5/2015
14:50
Gbb483 These look like ordinary market purchases. Surely, if the transactions related to their remuneration packages they would not be transacted at the prices prevailing on the dates of purchases. Incentive/bonus shares will usually be held for 3 or 4 years.
by nisbet on AstraZeneca
02/5/2015
10:28
Three directors getting shares as part of their renumeration package.
by gbb483 on AstraZeneca
01/5/2015
19:12
Three director share buys.
by nisbet on AstraZeneca
29/4/2015
13:50
Just added a few more AZN in my SIPP at £44.60. A c.10% fall in a matter of days seems a tad overdone to me.
by wirralowl on AstraZeneca
10/4/2015
17:11
Great spot thanks for sharing
by hydrus on AstraZeneca
10/4/2015
13:45
Wow what just happened
by hydrus on AstraZeneca
24/3/2015
15:24
Am I mistaken or are we back at the level achieved when Pfizer was making its bid!?
by bhoddhisattva on AstraZeneca
16/3/2015
08:36
Yep, that does appear to be the short term reaction. In the long term though I see this as a significant development, even if not exactly an unknown one, in validating Pascal Soriot's growth plans . It may take a few days , weeks who knows , but I'm believing that the market will see this is in a more positive light than it has today.
by dragonsteeth on AstraZeneca
16/3/2015
08:05
Looks like the Brillinta data was discounted in last weeks run up in price.Hey ho.
by steeplejack on AstraZeneca
15/3/2015
12:07
A short but very positive article in ST today om Brilinta , results from the Conference and sales hopes for future. All looking very good.
by dragonsteeth on AstraZeneca
15/3/2015
10:46
AstraZeneca's Brilinta plus aspirin reduces blood clot events in patients with a history of heart attackMar 14 2015, 20:32 ET | About: AstraZeneca Group plc (AZN) | By: Douglas W. House, SA News Editor Contact this editor with comments or a news tipA large scale outcomes study investigating AstraZeneca's (NYSE:AZN) anti-clotting agent, Brilinta (ticagrelor), plus low dose aspirin compared to placebo plus low dose aspirin for chronic secondary prevention of artherothrombotic (hardening and narrowing of the arteries) events in patients who had a heart attack one to three years prior to the enrolling in the study showed a statistically significant reduction in blood clot-related cardiovascular (CV) events compared to placebo.Both doses of Brilinta used in the study significantly reduced CV death, myocardial infarction (heart attack) or stroke compared to placebo. The rate at three years for the ticagrelor 90 mg arm was 7.85%; 7.77% for ticagrelor 60 mg and 9.04% for placebo (p=0.0043). A numerical decrease in the secondary endpoints of CV death and all-cause mortality was observed, but did not reach statistical significance.As expected with an oral antiplatelet, TIMI (thrombolysis in myocardial infarction) bleeding was higher in the ticagrelor arms than placebo. TIMI major bleeding rates were: 2.60% for ticagrelor 90 mg; 2.30% for ticagrelor 60 mg and 1.06% for placebo (p
by steeplejack on AstraZeneca
15/3/2015
10:41
Yes the sector's in vogue but the Brilinta data released over the weekend could see AZN sharply higher tomorrow.
by steeplejack on AstraZeneca
13/3/2015
07:35
Shire AND Astra did well yesterday, so its just general sentiment for pharmaceuticals.
by gbb483 on AstraZeneca
365  364  363  362  361  360  359  358  357  356  355  354  >>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 150529 11:05